Coronary disease & ACSSecondary analysis
Association Between Myocardial Infarction and Quality of Life in the ISCHEMIA Trial
- Secondary analysis of the ISCHEMIA randomised trial
- Median follow-up 36.2 months (Q1-Q3: 23.8-49.5 months)
Authors' conclusion
In ISCHEMIA, SMI was associated with reductions in both early and late generic and disease-specific QoL, whereas PMI was only associated with a transient reduction in disease-specific QoL.
Study context
- Population
- Randomised patients in the ISCHEMIA trialprimary analysis population
- Participants
- 4,375 patients
- Comparison
- PMI and SMI vs no myocardial infarction (MI)
- PMIn = 84
- SMIn = 352
Primary result
As reported in the abstract
Adjusted difference in quality of life (QoL) after MI
Adjusted difference, points (95% CI)
SMIearly EQ-5D VAS
−5.7(−7.3 to −4.1)
SMIlate EQ-5D VAS
−3.1(−4.3 to −1.9)
SMIearly SAQ-7
−7.7(−9.4 to −6.1)
SMIlate SAQ-7
−1.9(−3.2 to −0.7)
PMIearly EQ-5D VAS
−0.8(−3.3 to 1.8)
PMIlate EQ-5D VAS
−0.7(−2.7 to 1.2)
PMIearly SAQ-7
−3.0(−5.7 to −0.4)
PMIlate SAQ-7
−0.2(−2.2 to 1.8)
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Association Between Myocardial Infarction and Quality of Life in the ISCHEMIA Trial. JACC Cardiovasc Interv. Published 23 April 2025. doi:10.1016/j.jcin.2025.02.011
Summarised from the published abstract; every number is checked against it